PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to
View HTML
Toggle Summary GlycoMimetics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, 6,000,000 shares of its common stock
View HTML
Toggle Summary GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML
Company to provide update and host conference call today on clinical data to be presented at 2017 ASCO and EHA Meetings ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the release of abstracts containing new data from the ongoing Phase 2 clinical trial of its
View HTML
Toggle Summary GlycoMimetics' GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for treatment of adult relapsed/refractory acute myeloid leukemia (AML) to the company's drug candidate GMI-1271, an
View HTML
Toggle Summary GlycoMimetics Reports Program Updates and First Quarter 2017 Results
Completed enrollment in the first of two patient cohorts in the Phase 1/2 acute myeloid leukemia (AML) trial of GMI-1271 Presented preclinical data for GMI-1271 and GMI-1359 in multiple myeloma at AACR Annual Meeting 2017 Company management will host a conference call on Thursday, May 18,
View HTML
Toggle Summary GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma
Research demonstrates that E-selectin ligand in myeloma confers more aggressive disease and greater resistance to bortezomib (standard of care) GMI-1271 was able to restore sensitivity to bortezomib ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc.
View HTML
Toggle Summary GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the company will provide an update on clinical data from its Phase 1 and 2 studies of GMI-1271 at the 2017 American Society for Clinical Oncology in Chicago . GMI-1271 is an antagonist of E-selectin, for
View HTML
Toggle Summary GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors
Two Long-Time Board Members to Step Down After Company's 2017 Annual Meeting ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Scott Koenig , M.D., Ph.D., to its Board of Directors. Dr. Koenig is President and Chief Executive Officer and a
View HTML
Toggle Summary GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that the first of two patient cohorts in its Phase 2 acute myeloid leukemia (AML) trial of GMI-1271 has completed enrollment. This cohort is comprised of 25 patients 60 years of age or older with newly diagnosed
View HTML
Toggle Summary GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that pre-clinical research demonstrating the potential of two of its drug candidates, GMI-1271 and GMI-1359, against multiple myeloma will be shared via an oral presentation at the American Association for Cancer
View HTML